CoChat

Pathophysiology and Treatment of Prediabetes and Type 2 Diabetes in Youth

Bacha, Fida, Hannon, Tamara S., Tosur, Mustafa, Pike, Julie M., Butler, Ashley, Tommerdahl, Kalie L., Zeitler, Philip S. · 2024 · Diabetes Care
Cited by 57

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Youth-onset type 2 diabetes is a heterogeneous disease with increasing prevalence in relation to increased rates of obesity in children. It has genetic, epigenetic, social, and environmental determinants. Youth-onset type 2 diabetes is alarming given a rapidly progressive course compared with the course of adult-onset disease, early-onset vascular complications, and long-term exposure to hyperglycemia and associated complications. It is often preceded by prediabetes, a disease phase where defects in β-cell function relative to insulin sensitivity emerge. Herein, we review the current understanding of the pathophysiology of prediabetes and type 2 diabetes in youth. We describe the mechanisms underlying insulin resistance, the precipitous decline of β-cell function, and the role of other hormonal abnormalities in the pathogenesis of the disease. We discuss the critical importance of social determinants of health in the predisposition and progression of these conditions and present current management strategies and the advances in therapeutic approaches. These must adapt to meet the unique needs of the individual patient and family. Significant knowledge gaps remain that need to be addressed in future research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dci24-0029

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 66

  1. Kwak, 2024, Genetic architecture and biology of youth-onset type 2 diabetes, Nat Metab, 6, 226, 10.1038/s42255-023-00970-0 · DOI
  2. Bacha, 2024, Distinct amino acid profile characterizes youth with or at risk for type 2 diabetes, Diabetes, 73, 628, 10.2337/db23-0375 · DOI
  3. Bacha, 2021, Metabolic flexibility across the spectrum of glycemic regulation in youth, JCI Insight, 6, e146000
  4. Bacha, 2003, Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors, J Clin Endocrinol Metab, 88, 2534, 10.1210/jc.2002-021267 · DOI · Paper page
  5. D’Adamo, 2010, Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents, Diabetes Care, 33, 1817, 10.2337/dc10-0284 · DOI · Paper page
  6. Lawrence, 2011, Relationship of intramyocellular lipid to insulin sensitivity may differ with ethnicity in healthy girls and women, Obesity (Silver Spring), 19, 43, 10.1038/oby.2010.148 · DOI
  7. Tricò, 2018, Metabolic features of nonalcoholic fatty liver (NAFL) in obese adolescents: findings from a multiethnic cohort, Hepatology, 68, 1376, 10.1002/hep.30035 · DOI
  8. Castorani, 2020, Insulin resistance and type 2 diabetes in children, Ann Pediatr Endocrinol Metab, 25, 217, 10.6065/apem.2040090.045 · DOI
  9. Pulgaron, 2014, Obesity and type 2 diabetes in children: epidemiology and treatment, Curr Diab Rep, 14, 508, 10.1007/s11892-014-0508-y · DOI · Paper page
  10. Travers, 1995, Gender and Tanner stage differences in body composition and insulin sensitivity in early pubertal children, J Clin Endocrinol Metab, 80, 172
  11. Ball, 2006, Longitudinal changes in insulin sensitivity, insulin secretion, and beta-cell function during puberty, J Pediatr, 148, 16, 10.1016/j.jpeds.2005.08.059 · DOI · Paper page
  12. Bacha, 2010, From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation, Diabetes Care, 33, 2225, 10.2337/dc10-0004 · DOI · Paper page
  13. Cali', 2008, Metabolic abnormalities underlying the different prediabetic phenotypes in obese adolescents, J Clin Endocrinol Metab, 93, 1767, 10.1210/jc.2007-1722 · DOI · Paper page
  14. Bacha, 2012, Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study, Pediatr Diabetes, 13, 376, 10.1111/j.1399-5448.2011.00841.x · DOI · Paper page
  15. TODAY Study Group;, 2012, A clinical trial to maintain glycemic control in youth with type 2 diabetes, N Engl J Med, 366, 2247, 10.1056/NEJMoa1109333 · DOI · Paper page
  16. RISE Consortium Investigators, 2019, Effects of treatment of impaired glucose tolerance or recently diagnosed type 2 diabetes with metformin alone or in combination with insulin glargine on β-cell function: comparison of responses in youth and adults, Diabetes, 68, 1670
  17. RISE Consortium, 2018, Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: I. observations using the hyperglycemic clamp, Diabetes Care, 41, 1696, 10.2337/dc18-0244 · DOI · Paper page
  18. RISE Consortium, 2018, Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: II. Observations using the oral glucose tolerance test, Diabetes Care, 41, 1707, 10.2337/dc18-0243 · DOI · Paper page
  19. Utzschneider, 2020, β-Cells in youth with impaired glucose tolerance or early type 2 diabetes secrete more insulin and are more responsive than in adults, Pediatr Diabetes, 21, 1421, 10.1111/pedi.13113 · DOI
  20. TODAY Study Group, 2021, Postintervention effects of varying treatment arms on glycemic failure and β-cell function in the TODAY trial, Diabetes Care, 44, 75, 10.2337/dc20-0622 · DOI
  21. Weiss, 2011, Basal alpha-cell up-regulation in obese insulin-resistant adolescents, J Clin Endocrinol Metab, 96, 91, 10.1210/jc.2010-1275 · DOI · Paper page
  22. Michaliszyn, 2014, β-Cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes, Diabetes, 63, 3846, 10.2337/db13-1951 · DOI · Paper page
  23. Holst, 2009, The incretin system and its role in type 2 diabetes mellitus, Mol Cell Endocrinol, 297, 127, 10.1016/j.mce.2008.08.012 · DOI · Paper page
  24. Knop, 2007, Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?, Diabetes, 56, 1951, 10.2337/db07-0100 · DOI · Paper page
  25. Kim, 2008, Role of mitochondrial dysfunction in insulin resistance, Circ Res, 102, 401, 10.1161/CIRCRESAHA.107.165472 · DOI · Paper page
  26. Mukai, 2022, Role of reactive oxygen species in glucose metabolism disorder in diabetic pancreatic β-cells, Biomolecules, 12, 1228, 10.3390/biom12091228 · DOI
  27. Turer, 2012, Adiponectin: mechanistic insights and clinical implications, Diabetologia, 55, 2319, 10.1007/s00125-012-2598-x · DOI · Paper page
  28. Bacha, 2004, Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and β-cell function, Diabetes Care, 27, 547, 10.2337/diacare.27.2.547 · DOI · Paper page
  29. Butler, 2017, Social determinants of health and racial/ethnic disparities in type 2 diabetes in youth, Curr Diab Rep, 17, 60, 10.1007/s11892-017-0885-0 · DOI · Paper page
  30. Deschênes, 2018, Adverse childhood experiences and the risk of diabetes: examining the roles of depressive symptoms and cardiometabolic dysregulations in the Whitehall II cohort study, Diabetes Care, 41, 2120, 10.2337/dc18-0932 · DOI
  31. Shomaker, 2011, Longitudinal study of depressive symptoms and progression of insulin resistance in youth at risk for adult obesity, Diabetes Care, 34, 2458, 10.2337/dc11-1131 · DOI · Paper page
  32. Walders-Abramson, 2014, Relationships among stressful life events and physiological markers, treatment adherence, and psychosocial functioning among youth with type 2 diabetes, J Pediatr, 165, 504, 10.1016/j.jpeds.2014.05.020 · DOI
  33. Ievers-Landis, 2015, Longitudinal correlates of health risk behaviors in children and adolescents with type 2 diabetes, J Pediatr, 166, 1258, 10.1016/j.jpeds.2015.01.019 · DOI
  34. TODAY Study Group, 2013, Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial, Diabetes Care, 36, 1735, 10.2337/dc12-2420 · DOI · Paper page
  35. Dabelea, 2017, Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood, JAMA, 317, 825, 10.1001/jama.2017.0686 · DOI · Paper page
  36. Al-Saeed, 2016, An inverse relationship between age of type 2 diabetes onset and complication risk and mortality: the impact of youth-onset type 2 diabetes, Diabetes Care, 39, 823, 10.2337/dc15-0991 · DOI · Paper page
  37. Styne, 2017, Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society Clinical practice guideline, J Clin Endocrinol Metab, 102, 709, 10.1210/jc.2016-2573 · DOI · Paper page
  38. Garnett, 2013, Optimal macronutrient content of the diet for adolescents with prediabetes; RESIST a randomised control trial, J Clin Endocrinol Metab, 98, 2116, 10.1210/jc.2012-4251 · DOI
  39. Perkison, 2018, Dietary interventions and type 2 diabetes in youth: a fresh look at the evidence, Curr Nutr Rep, 7, 227, 10.1007/s13668-018-0241-2 · DOI
  40. Kriska, 2018, Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes, Pediatr Diabetes, 19, 36, 10.1111/pedi.12526 · DOI
  41. Dorenbos, 2021, Effect of a high protein/low glycaemic index diet on insulin resistance in adolescents with overweight/obesity-a PREVIEW randomized clinical trial, Pediatr Obes, 16, e12702, 10.1111/ijpo.12702 · DOI
  42. Mayer-Davis, 2001, Low-fat diets for diabetes prevention, Diabetes Care, 24, 613, 10.2337/diacare.24.4.613 · DOI
  43. Marson, 2016, Effects of aerobic, resistance, and combined exercise training on insulin resistance markers in overweight or obese children and adolescents: a systematic review and meta-analysis, Prev Med, 93, 211, 10.1016/j.ypmed.2016.10.020 · DOI
  44. Herbst, 2015, Impact of regular physical activity on blood glucose control and cardiovascular risk factors in adolescents with type 2 diabetes mellitus--a multicenter study of 578 patients from 225 centres, Pediatr Diabetes, 16, 204, 10.1111/pedi.12144 · DOI
  45. Slaght, 2021, Physical activity and cardiometabolic health in adolescents with type 2 diabetes: a cross-sectional study, BMJ Open Diabetes Res Care, 9, e002134, 10.1136/bmjdrc-2021-002134 · DOI
  46. Savoye, 2014, Reversal of early abnormalities in glucose metabolism in obese youth: results of an intensive lifestyle randomized controlled trial, Diabetes Care, 37, 317, 10.2337/dc13-1571 · DOI · Paper page
  47. Peña, 2022, Effects of a diabetes prevention program on type 2 diabetes risk factors and quality of life among Latino youths with prediabetes: a randomized clinical trial, JAMA Netw Open, 5, e2231196, 10.1001/jamanetworkopen.2022.31196 · DOI
  48. Kenney, 2016, The impact of a home-based diabetes prevention and management program on high-risk American Indian youth, Diabetes Educ, 42, 585, 10.1177/0145721716658357 · DOI
  49. Love-Osborne, 2018, Longitudinal follow up of dysglycemia in overweight and obese pediatric patients, Pediatr Diabetes, 19, 199, 10.1111/pedi.12570 · DOI · Paper page
  50. Garnett, 2014, Improved insulin sensitivity and body composition, irrespective of macronutrient intake, after a 12 month intervention in adolescents with pre-diabetes; RESIST a randomised control trial, BMC Pediatr, 14, 289, 10.1186/s12887-014-0289-0 · DOI · Paper page
  51. Marcus, 2017, Weight change in the management of youth-onset type 2 diabetes: the TODAY clinical trial experience, Pediatr Obes, 12, 337, 10.1111/ijpo.12148 · DOI
  52. Shomaker, 2016, A randomized controlled trial to prevent depression and ameliorate insulin resistance in adolescent girls at risk for type 2 diabetes, Ann Behav Med, 50, 762, 10.1007/s12160-016-9801-0 · DOI
  53. Glazier, 2006, A systematic review of interventions to improve diabetes care in socially disadvantaged populations, Diabetes Care, 29, 1675, 10.2337/dc05-1942 · DOI · Paper page
  54. Bacha, 2018, Initial presentation of type 2 diabetes in adolescents predicts durability of successful treatment with metformin monotherapy: insights from the Pediatric Diabetes Consortium T2D Registry, Horm Res Paediatr, 89, 47, 10.1159/000481687 · DOI
  55. Tamborlane, 2019, Liraglutide in children and adolescents with type 2 diabetes, N Engl J Med, 381, 637, 10.1056/NEJMoa1903822 · DOI · Paper page
  56. Tamborlane, 2022, Once-weekly exenatide in youth with type 2 diabetes, Diabetes Care, 45, 1833, 10.2337/dc21-2275 · DOI · Paper page
  57. Arslanian, 2022, Once-weekly dulaglutide for the treatment of youths with type 2 diabetes, N Engl J Med, 387, 433, 10.1056/NEJMoa2204601 · DOI · Paper page
  58. Thornberry, 2009, Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4), Best Pract Res Clin Endocrinol Metab, 23, 479, 10.1016/j.beem.2009.03.004 · DOI · Paper page
  59. Laffel, 2023, Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial, Lancet Diabetes Endocrinol, 11, 169, 10.1016/S2213-8587(22)00387-4 · DOI · Paper page
  60. Klein, 2014, Liraglutide’s safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial, Diabetes Technol Ther, 16, 679, 10.1089/dia.2013.0366 · DOI · Paper page
  61. Shehadeh, 2023, Dapagliflozin or saxagliptin in pediatric type 2 diabetes, NEJM Evid, 2, 10.1056/EVIDoa2300210 · DOI
  62. Tamborlane, 2022, Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study, Lancet Diabetes Endocrinol, 10, 341, 10.1016/S2213-8587(22)00052-3 · DOI
  63. Hampl, 2023, Executive summary: clinical practice guideline for the evaluation and treatment of children and adolescents with obesity, Pediatrics, 151, e2022060641, 10.1542/peds.2022-060641 · DOI
  64. Bensignor, 2022, Anti-obesity pharmacotherapy for treatment of pediatric type 2 diabetes: review of the literature and lessons learned from adults, Front Endocrinol (Lausanne), 13, 1043650, 10.3389/fendo.2022.1043650 · DOI
  65. Kelly, 2022, Phentermine/topiramate for the treatment of adolescent obesity, NEJM Evid, 1, 10.1056/evidoa2200014, 10.1056/EVIDoa2200014 · DOI · Paper page
  66. Miras, 2013, Mechanisms underlying weight loss after bariatric surgery, Nat Rev Gastroenterol Hepatol, 10, 575, 10.1038/nrgastro.2013.119 · DOI · Paper page

Cited by

See all 57

Metadata

Authors
Bacha, F., Hannon, T. S., Tosur, M., Pike, J. M., Butler, A., Tommerdahl, K. L., & Zeitler, P. S.
Affiliations
  • 1USDA/ARS Children’s Nutrition Research Center, Baylor College of Medicine, Houston, TX
  • 3Division of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN
  • 5Division of Psychology, Department of Pediatrics, Texas Children’s Hospital, Baylor College of Medicine, Houston, TX
  • 6Section of Endocrinology, Department of Pediatrics, Children’s Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, CO
Venue
Diabetes Care
Published
2024-09-09
Volume
47
Issue
12
Pages
2038-2049
ISSN
  • 0149-5992
  • 1935-5548
Cited by
57
References
33
Language
en
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK134982 (FB), K23-DK129821 (MT))
  • Agricultural Research Service (CRIS Award 309251000-057-03S (FB))
  • National Institute of Child Health and Human Development (HD105104-01 (FB))

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pathophysiology and Treatment of Prediabetes and Type 2 Diabetes in Youth. https://app.cochat.ai/papers/10.2337/dci24-0029
The paper
Bacha, F., Hannon, T. S., Tosur, M., Pike, J. M., Butler, A., Tommerdahl, K. L., & Zeitler, P. S. (2024). Pathophysiology and Treatment of Prediabetes and Type 2 Diabetes in Youth. Diabetes Care. https://doi.org/10.2337/dci24-0029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.